Results 151 to 160 of about 38,450 (306)

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, EarlyView.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. [PDF]

MAbs
Danquah W, Pichery M, Eden T, Boyance A, Pasquet L, Roure V, Mars M, Marchand A, Gumz E, Gador M, Valente L, Contini M, Czernecki L, Shanmuganathan S, Barron P, Chabot S, Dangl M, Niederfellner G.   +17 more
europepmc   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

British Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas, Mikkel Werling, Casper M. Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben‐Dali, Mariam H. Hleuhel, Christian Brieghel, Carsten U. Niemann, Caspar da Cunha‐Bang   +9 more
wiley   +1 more source

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. [PDF]

Hemasphere
Vega G, Morillo D, Riedhammer C, Smits F, Bag A, Julian K, Gomis NT, Gaisan CM, Bermudez MA, Shah MR, Mohyuddin GR, Dhakal B, Rasche L, Schinke C, D'Souza A, Szabo A, van de Donk NWCJ, Chakraborty R, Mohan M.   +18 more
europepmc   +1 more source

Plasmacytic markers as immunotherapeutic targets for primary CD20‐negative aggressive B‐cell lymphomas

British Journal of Haematology, EarlyView.
Frank Neumann, Claudia Schormann, Onur Cetin, Igor A. Kos, Moritz Bewarder, Eva C. Schwarz, Stefan Lohse, Stephanie Maurer, Philipp B. Staber, Joerg T. Bittenbring, Sigrun Smola, Konstantinos Christofyllakis, Markus Hoth, Lorenz Thurner   +13 more
wiley   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: how should this regimen be positioned in current treatment algorithms? [PDF]

Transl Cancer Res
Tsuda M, Kiyasu J.
europepmc   +1 more source

Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL?

British Journal of Haematology, EarlyView.
Maria Dimou, Theodoros P. Vassilakopoulos   +1 more
wiley   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle^TM variants. [PDF]

MAbs
Sela T, Wirth T, Sommer A, Larraillet V, Butzer J, Lohmann S, Wittmann P, Klein C, Knoetgen H, Villasenor R, Indlekofer A, Hofer K, Schumacher F, Niewöhner J.   +13 more
europepmc   +1 more source